Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05903937

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases (HAITILS-PHP)

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes Preconditioned With Percutaneous Hepatic Perfusion With Melphalan in Patients With Melanoma and Liver Metastases

Sponsor: Vastra Gotaland Region

Conditions Metastatic Cutaneous Melanoma Uveal Melanoma

Interventions Autologous Tumor Infiltrating Lymphocytes Interleukin-2 Melphalan

Updated 3 times since 2023 Last updated: Jun 5, 2023 Started: Dec 31, 2023 Primary completion: Dec 31, 2024 Completion: Dec 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metastatic Cutaneous Melanoma and Uveal Melanoma and is currently actively recruiting participants. Vastra Gotaland Region leads this study, which shows 3 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
Jul 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vastra Gotaland Region

Data source: Vastra Gotaland Region

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.